CUREVAC NV (CVAC) Fundamental Analysis & Valuation

NASDAQ:CVAC • NL0015436031

4.66 USD
-0.01 (-0.21%)
At close: Jan 5, 2026
4.62 USD
-0.04 (-0.86%)
After Hours: 1/5/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CVAC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CVAC. CVAC was compared to 519 industry peers in the Biotechnology industry. Both the profitability and the financial health of CVAC get a neutral evaluation. Nothing too spectacular is happening here. CVAC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

5

1. CVAC Profitability Analysis

1.1 Basic Checks

  • In the past year CVAC has reported negative net income.
  • In the past year CVAC has reported a negative cash flow from operations.
  • In the past 5 years CVAC reported 4 times negative net income.
  • In multiple years CVAC reported negative operating cash flow during the last 5 years.
CVAC Yearly Net Income VS EBIT VS OCF VS FCFCVAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M -800M

1.2 Ratios

  • CVAC has a better Return On Assets (11.31%) than 93.77% of its industry peers.
  • The Return On Equity of CVAC (14.79%) is better than 94.53% of its industry peers.
  • With an excellent Return On Invested Capital value of 14.12%, CVAC belongs to the best of the industry, outperforming 95.47% of the companies in the same industry.
Industry RankSector Rank
ROA 11.31%
ROE 14.79%
ROIC 14.12%
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
CVAC Yearly ROA, ROE, ROICCVAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

  • The Profit Margin of CVAC (182.11%) is better than 98.49% of its industry peers.
  • CVAC's Operating Margin of 212.01% is amongst the best of the industry. CVAC outperforms 100.00% of its industry peers.
  • The Gross Margin of CVAC (93.01%) is better than 93.40% of its industry peers.
Industry RankSector Rank
OM 212.01%
PM (TTM) 182.11%
GM 93.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVAC Yearly Profit, Operating, Gross MarginsCVAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CVAC Health Analysis

2.1 Basic Checks

  • CVAC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for CVAC remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, CVAC has more shares outstanding
  • CVAC has a better debt/assets ratio than last year.
CVAC Yearly Shares OutstandingCVAC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CVAC Yearly Total Debt VS Total AssetsCVAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 4.23 indicates that CVAC is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of CVAC (4.23) is better than 71.70% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that CVAC is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.03, CVAC is in line with its industry, outperforming 42.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACC1.96
WACC7.21%
CVAC Yearly LT Debt VS Equity VS FCFCVAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

  • A Current Ratio of 3.70 indicates that CVAC has no problem at all paying its short term obligations.
  • CVAC has a Current ratio (3.70) which is in line with its industry peers.
  • A Quick Ratio of 3.69 indicates that CVAC has no problem at all paying its short term obligations.
  • CVAC has a Quick ratio (3.69) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.69
CVAC Yearly Current Assets VS Current LiabilitesCVAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. CVAC Growth Analysis

3.1 Past

  • The earnings per share for CVAC have decreased strongly by -247.92% in the last year.
  • CVAC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.98%.
  • Measured over the past years, CVAC shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%

3.2 Future

  • The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
  • Based on estimates for the next years, CVAC will show a very negative growth in Revenue. The Revenue will decrease by -11.14% on average per year.
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CVAC Yearly Revenue VS EstimatesCVAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CVAC Yearly EPS VS EstimatesCVAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. CVAC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CVAC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVAC Price Earnings VS Forward Price EarningsCVAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CVAC is valued cheaply inside the industry as 99.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.08
CVAC Per share dataCVAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • CVAC's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CVAC Dividend Analysis

5.1 Amount

  • No dividends for CVAC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CVAC Fundamentals: All Metrics, Ratios and Statistics

CUREVAC NV

NASDAQ:CVAC (1/5/2026, 8:00:00 PM)

After market: 4.62 -0.04 (-0.86%)

4.66

-0.01 (-0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)04-08
Inst Owners10.45%
Inst Owner Change-75.38%
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap1.05B
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts74.55
Price Target5.57 (19.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.69%
Min EPS beat(2)-39.67%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)1.84%
Min EPS beat(4)-39.67%
Max EPS beat(4)35.41%
EPS beat(8)3
Avg EPS beat(8)1.3%
EPS beat(12)5
Avg EPS beat(12)-6.32%
EPS beat(16)8
Avg EPS beat(16)6.13%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)16.57%
PT rev (3m)13.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)0%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)20.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.77
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.07
EV/EBITDA 3.08
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.36
BVpS4.49
TBVpS4.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 11.31%
ROE 14.79%
ROCE 16.62%
ROIC 14.12%
ROICexc 26.37%
ROICexgc 27.79%
OM 212.01%
PM (TTM) 182.11%
GM 93.01%
FCFM N/A
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.18
Cap/Depr 28.09%
Cap/Sales 7.01%
Interest Coverage 66.45
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.69
Altman-Z 4.23
F-Score3
WACC7.21%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A

CUREVAC NV / CVAC FAQ

Can you provide the ChartMill fundamental rating for CUREVAC NV?

ChartMill assigns a fundamental rating of 4 / 10 to CVAC.


Can you provide the valuation status for CUREVAC NV?

ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (CVAC). This can be considered as Overvalued.


How profitable is CUREVAC NV (CVAC) stock?

CUREVAC NV (CVAC) has a profitability rating of 5 / 10.


What is the financial health of CUREVAC NV (CVAC) stock?

The financial health rating of CUREVAC NV (CVAC) is 5 / 10.


What is the expected EPS growth for CUREVAC NV (CVAC) stock?

The Earnings per Share (EPS) of CUREVAC NV (CVAC) is expected to decline by -163.99% in the next year.